Yahoo
HKSE - Delayed Quote HKD

Clover Biopharmaceuticals, Ltd. (2197.HK)

1.250 -0.040 (-3.10%)
At close: October 30 at 4:08:06 PM GMT+8

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
Name Title Pay Exercised Year Born
Dr. Peng Liang Ph.D.
Founder, Chief Scientific Officer & Chairman of the Board 4.52M -- 1961
Mr. Joshua G. Liang
CEO & Executive Director 2.31M -- 1993
Dr. Yang Li Ph.D.
Chief Technology Officer -- -- --
Ms. Htay Htay Han MBBS
Chief Medical Officer of Vaccine -- -- 1969
Dr. Berry Michael Ph.D.
Chief Technical Operation Officer -- -- 1966
Ms. Tracy Wang
Senior Vice President of Head of Regulatory Affairs, China -- -- --
Dr. Nicholas Jackson M.Sc., Ph.D.
President of Global R&D and Alliances -- -- 1971
Mr. LiongHo Chua
President of Greater China -- -- 1964
Dr. Igor Smolenov M.D., Ph.D.
Executive Vice President of Global Clinical Development Vaccines -- -- --
Mr. Nicolas Burdin Ph.D.
Global Head of R&D -- -- --

Clover Biopharmaceuticals, Ltd.

No. 758 West Nanjing Road
Room 1901 Jing'an District
Shanghai
China
https://www.cloverbiopharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
257

Description

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company's product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza; and SCB-219M, a thrombocytopenia receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, the company sells biopharmaceutical drugs. The company was founded in 2007 and is headquartered in Shanghai, the People's Republic of China.

Corporate Governance

Clover Biopharmaceuticals, Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

April 29, 2026 at 12:00 AM UTC

D: Additional Forms

April 28, 2025 at 12:00 AM UTC

D/A: Additional Forms

April 12, 2024 at 12:00 AM UTC

D: Additional Forms

May 9, 2023 at 12:00 AM UTC

D/A: Additional Forms

May 24, 2022 at 12:00 AM UTC

D/A: Additional Forms

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: